Navigation Links
A new study suggests that a neurotransmitter might improve the treatment of cancer
Date:12/5/2011

COLUMBUS, Ohio Doses of a neurotransmitter might offer a way to boost the effectiveness of anticancer drugs and radiation therapy, according to a new study led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

Using animal models of human breast and prostate cancers, the researchers found that injections of the neurotransmitter dopamine can improve blood flow to tumors and improve delivery of an anticancer drug, doubling the drug's concentration in tumors and increasing its effectiveness. The increased blood flow also raised tumor oxygen levels, a condition that typically improves the effectiveness of both chemotherapy and radiation therapy.

The study also found that dopamine plays an important role in maintaining the structure of normal blood vessels, and that it does this by working through the D2 dopamine receptor, which is present in normal blood-vessel cells called endothelial cells and pericytes. Dopamine was absent in tumor blood-vessel cells.

The findings are published online in the Proceedings of the National Academy of Sciences.

"Our study indicates a use for dopamine in the treatment of cancer and perhaps other disorders in which normalizing abnormal and dysfunctional blood vessels might improve therapeutic responses," says Dr. Sujit Basu, associate professor of pathology and a researcher in the OSUCCC James Experimental Therapeutics Program.

"Since dopamine and related agents are already used in the clinic for other disorders, these comparatively inexpensive drugs might be applied to the treatment of cancer to increase the therapeutic responses of chemotherapy and radiotherapy," he says.

The blood vessels that develop inside tumors are structurally abnormal, chaotic and leaky and do a poor job of supplying blood to the tumor, Basu notes. This hinders the delivery of chemotherapeutic agents, and it leaves tumors oxygen deprived. This oxygen deprivation makes tumor cells resistant to chemotherapy and radiation.

Basu and his colleagues found that the dopamine treatment normalizes the structure of abnormal tumor blood vessels, indicating an important role for a neurotransmitter in the remodeling of blood vessels. Other key findings include the following:

  • The tumor tissue used in the study showed the absence of dopamine.
  • After dopamine treatment, tumor blood vessels in both cases resembled normal vessels in regard to leakiness and architecture. Pretreatment with a dopamine receptor antagonist negated this effect.
  • Subcutaneous human colon tumors in mice treated with dopamine and the chemotherapeutic drug 5-fluorouracil (5-FU) accumulated twice the amount of 5-FU as tumors in mice treated with the drug only.
  • Subcutaneous human colon tumors in mice treated with both dopamine and 5-FU were less than one-third the size of tumors in mice treated with 5-FU only.

"Overall, our findings suggest that the normalization of tumor blood vessels using the neurotransmitter dopamine might be an important approach for improving therapeutic efficacy in the treatment of cancer patients," Basu says.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Study finds headaches after traumatic brain injury highest in adolescents and girls
2. Maryland study finds that US Hispanics were at greater risk for H1N1 flu during 2009 pandemic
3. Fetal Exposure to Epilepsy Drug Might Raise Autism Risk: Study
4. U.S. School Kids Often Miss Out on Recess, Study Finds
5. Study Sees Rice as Source of Arsenic Exposure
6. Risk for Dementia Rises When Diabetes, Depression Meet: Study
7. University of Kentucky researchers awarded CDC grant to study cancer survival in Appalachia
8. Follow-up study finds prolonged fatigue for those who had chemotherapy for breast cancer
9. More Children Using Preventive Asthma Drugs: Study
10. 3-D TV Doesnt Raise Seizure Risk for Kids With Epilepsy: Study
11. New gene study of ADHD points to defects in brain signaling pathways
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES ... has announced that Mercy Medical Center will serve as the official title sponsor of ... On Sunday, June 25, 2017, thousands of women will walk or run the course ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sublime Naturals ... "Spice of Life" or "Wonder Spice", it has been used for thousands of years. ... the East," says Heshelow, author of " Turmeric: How to Use it For Your ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... educational opportunities for attending prescribers at the upcoming World Congress, in Hollywood Florida ... has always been recognized as the visionary leader in the training of physicians, ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental team ... patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, porcelain ... the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, Milton ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... in Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. ... to traditional orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017 Varian Medical Systems (NYSE: ... for the second quarter of fiscal year 2017 following the ... news release will be followed by a teleconference available to ... and a link to the conference call webcast will be ... access the teleconference call and replay: ...
(Date:3/29/2017)... 2017  Spiral Therapeutics, Inc. today announced the ... S.L. for the worldwide exclusive rights to Bionure,s ... field of otolaryngology for aggregate payments of up ... agreement provides Spiral with the option to license ... profile. Under the terms of the agreement, Spiral ...
(Date:3/29/2017)... , March 29, 2017   Dynatronics Corporation ... the appointment of Cynthia L. McHenry ... be responsible for leading Dynatronics manufacturing, distribution, and ... report to Dynatronics, CEO Kelvyn H. Cullimore, ... an extensive search process conducted by the company ...
Breaking Medicine Technology: